
Lam Research Corporation (LRCX), a large-cap growth stock in the Semiconductors industry, has received an 86% rating from Validea's Patient Investor model, which is based on Warren Buffett's investment strategy. This score, indicating 'some interest' for the strategy, highlights LRCX's strong underlying fundamentals and reasonable valuation, aligning with the model's focus on predictable profitability and low debt.
Lam Research Corporation (LRCX) scores an 86% on Validea's Patient Investor model, which is based on the investment principles of Warren Buffett. This score, falling into the 'some interest' category (defined as 80-90%), signals that the large-cap semiconductor firm exhibits strong underlying fundamentals and a reasonable valuation. The analysis highlights LRCX's alignment with the strategy's focus on predictable, long-term profitability and low debt. The company successfully passed eight key criteria, including earnings predictability, debt service capacity, return on equity, free cash flow generation, effective use of retained earnings, and shareholder-friendly share repurchases. However, the report also flags a specific area of weakness, as LRCX failed the test for Return on Total Capital, indicating a potential inefficiency in its use of its complete capital base. Despite being classified as a growth stock in a cyclical industry, its profile largely meets the criteria for a durable, high-quality business.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment